Pages that link to "Q39264662"
Jump to navigation
Jump to search
The following pages link to The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity (Q39264662):
Displaying 50 items.
- Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept (Q26786766) (← links)
- Defining response to anti-VEGF therapies in neovascular AMD (Q26996510) (← links)
- Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel (Q26999836) (← links)
- Disease severity in newly diagnosed glaucoma patients with visual field loss: trends from more than a decade of data (Q30882123) (← links)
- Are rates of vision loss in patients in English glaucoma clinics slowing down over time? Trends from a decade of data (Q30990445) (← links)
- I-Maculaweb: A Tool to Support Data Reuse in Ophthalmology. (Q31095589) (← links)
- Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment (Q33825687) (← links)
- Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases (Q33840787) (← links)
- Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis (Q33910289) (← links)
- Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results (Q35196822) (← links)
- Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom (Q35196853) (← links)
- The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes (Q35604653) (← links)
- The Chronic Care for Wet Age Related Macular Degeneration (CHARMED) Study: A Randomized Controlled Trial (Q35841740) (← links)
- Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab Injection (Q35897929) (← links)
- Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting (Q36053791) (← links)
- Optical Coherence Tomography in the UK Biobank Study - Rapid Automated Analysis of Retinal Thickness for Large Population-Based Studies (Q36157730) (← links)
- A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. (Q36473604) (← links)
- Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes (Q36763595) (← links)
- Kilovoltage radiosurgery with gold nanoparticles for neovascular age-related macular degeneration (AMD): a Monte Carlo evaluation. (Q36803774) (← links)
- GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration (Q37444127) (← links)
- Six-year outcomes in neovascular age-related macular degeneration with ranibizumab (Q37578627) (← links)
- A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom (Q37699709) (← links)
- Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration. (Q38367104) (← links)
- Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration (Q38527401) (← links)
- Ranibizumab for the treatment of wet AMD: a summary of real-world studies (Q38592591) (← links)
- Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration (Q38712425) (← links)
- One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration. (Q38967707) (← links)
- Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents (Q38975099) (← links)
- Assessment of visual distortions in age-related macular degeneration: emergence of new approaches (Q38979931) (← links)
- Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements (Q38996254) (← links)
- A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab. (Q39285726) (← links)
- The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. (Q39598982) (← links)
- UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections (Q39876159) (← links)
- Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK. (Q40783264) (← links)
- A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration (Q41504310) (← links)
- Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma (Q41947480) (← links)
- Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials (Q42602540) (← links)
- Response to 'Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the U.S.A.'. (Q42616968) (← links)
- Big Data and Uveitis (Q42734776) (← links)
- Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia. (Q47124190) (← links)
- Gaming to improve vision: 21st century self-monitoring for patients with age-related macular degeneration. (Q47355167) (← links)
- Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom (Q47632636) (← links)
- Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy (Q47936744) (← links)
- Induced pluripotent stem cell-based therapy for age-related macular degeneration. (Q48218214) (← links)
- Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline (Q48293183) (← links)
- Hyperpigmented spots after treatment for submacular hemorrhage secondary to polypoidal choroidal vasculopathy (Q48305920) (← links)
- Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab (Q48520571) (← links)
- Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting. (Q50091849) (← links)
- Real world evidence of use of anti-VEGF therapy in Denmark (Q50571685) (← links)
- The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK. (Q51616989) (← links)